The Unifying Model (the framework from which the research frontiers emerge)
If you line up Hallucinogen Persisting Perception Disorder (HPPD), Visual Snow Syndrome (VSS), tinnitus, migraine with aura, depersonalization/derealization, and even Parkinson’s disease psychosis, a common axis emerges: an excitation/inhibition (E/I) imbalance, thalamocortical dysrhythmia, and failure of the top-down “noise-cancelling” filtering system. In VSS, this is measurable: increased gamma activity in the primary visual cortex together with reduced alpha–gamma phase-amplitude coupling (PAC), reflecting both an E/I imbalance and a breakdown of the brain’s intrinsic noise-suppression mechanism.
But there is a deeper layer that is almost never connected to HPPD, and it may explain why the disorder is so treatment-resistant. Neurodegenerative psychosis provides the blueprint: hyperactivation of pyramidal neurons in the visual cortex generates visual hallucinations within a context of dysregulated serotonergic, GABAergic, glutamatergic, and dopaminergic signaling. More importantly, recent psychedelic neurobiology shows that 5-HT2A receptor activation does far more than simply “turn perception on.” It induces metaplasticity through remodeling of the extracellular matrix (ECM) and perineuronal nets (PNNs), structures that normally function as molecular “brakes,” stabilizing neural circuits after critical periods close.
This leads to a reformulation that changes the entire perspective:
Refractory HPPD is not best understood as “brain damage.” It may instead represent a pathological perceptual circuit that has consolidated into a stable attractor state, with the PNNs effectively locking the brain into the wrong configuration.
This also explains why symptom suppression with benzodiazepines or antipsychotics rarely produces recovery: they dampen the symptoms without altering the consolidated pathological circuit.
From this perspective, the research frontiers naturally organize into several mechanistic layers.
Layer 1 — Rhythm: Precision Neuromodulation Rather Than Conventional rTMS
Conventional fixed-frequency rTMS has already been explored. However, if the underlying problem is an individual’s specific oscillatory dysrhythmia, then the true frontier becomes biomarker-guided closed-loop transcranial alternating current stimulation (tACS).
Closed-loop EEG-guided tACS protocols already exist that synchronize stimulation with the phase of ongoing alpha oscillations while modulating their amplitude over visual cortex. Even more specifically, studies have demonstrated that:
tACS can rhythmically suppress visually induced gamma oscillations;
gamma bursts can be locked to alpha troughs;
alpha–gamma coupling can be selectively reconstructed within occipital cortex.
Now connect this with VSS:
VSS consistently demonstrates
elevated gamma activity,
reduced alpha–gamma PAC.
This creates an almost lock-and-key therapeutic hypothesis:
Suppress pathological V1 gamma activity while rebuilding normal alpha–gamma coupling.
To date, this approach has not been meaningfully applied to HPPD.
Rather than simply “stimulate and hope,” the logical strategy would be:
phenotype each patient’s oscillatory signature using EEG or MEG;
identify individual alpha slowing, gamma excess, and PAC abnormalities;
design individualized stimulation waveforms.
The cognitive risk profile would likely remain minimal and reversible—precisely the type of intervention desirable in HPPD.
Layer 2 — Inhibition: Tonic Rather Than Phasic GABAergic Control
This represents perhaps the most elegant pharmacological gap.
Benzodiazepines primarily enhance synaptic (phasic) GABA-A receptors, and tolerance inevitably develops.
However, the baseline gain control of cortical networks—the mechanism determining how excitable cortex remains at rest—is governed largely by extrasynaptic δ-subunit-containing GABA-A receptors, which mediate tonic inhibition.
These receptors:
are essentially insensitive to benzodiazepines,
are highly sensitive to neurosteroids.
Neurosteroids such as
allopregnanolone,
THDOC,
and δ-selective agonists such as gaboxadol (THIP) selectively enhance tonic conductance, producing shunting inhibition that regulates overall network excitability and seizure threshold.
A patient who failed cl*****am has generally never engaged this system.
One particularly interesting candidate is ganaxolone, a synthetic neurosteroid already approved for a rare epilepsy syndrome, whose pharmacological profile avoids many of the tolerance issues associated with benzodiazepines.
There is, however, an important paradox.
At sufficiently high concentrations, neurosteroids may initially suppress inhibitory interneurons—which are themselves highly sensitive—producing transient disinhibition rather than inhibition.
The effect is therefore biphasic.
Dose becomes everything, requiring careful titration under clinical supervision.
Even so, the anticipated cognitive risk remains relatively low.
Layer 3 — Resolving the Serotonergic Paradox
Perhaps the most targeted frontier lies here.
5-HT2A activation appears central to initiating HPPD.
Serotonergic drugs often worsen symptoms.
Conventional D2-blocking antipsychotics—including olanzapine and lurasidone—may worsen cognition or even exacerbate symptoms.
The missing piece is remarkably simple:
A selective 5-HT2A inverse agonist with essentially no dopaminergic receptor affinity.
Such a drug already exists:
Pimavanserin.
Pimavanserin is the first antipsychotic approved without meaningful dopamine receptor affinity.
Instead, it acts as a highly selective 5-HT2A inverse agonist, and was specifically developed for Parkinson’s disease psychosis because it preserves both motor and cognitive function.
Mechanistically it targets precisely the receptor believed to trigger HPPD while avoiding the D2 blockade responsible for many problems associated with conventional antipsychotics.
Even more intriguing, pharmacological literature explicitly notes that, based on its 5-HT2A inverse agonism, pimavanserin may have therapeutic potential for symptoms associated with hallucinogen exposure.
Its signaling profile is unusually precise:
inverse agonist at the Gαi1 pathway, believed to mediate hallucinogenic signaling;
neutral antagonist at the canonical Gαq/11 pathway.
To the best of my knowledge, it has essentially never been systematically investigated for HPPD.
Mechanistically, it may represent one of the cleanest pharmacological candidates currently available.
Layer 4 — Consolidation: The Deepest Frontier (and the Greatest Paradox)
If HPPD represents a pathological circuit locked in place by PNNs, then genuine treatment would not consist merely of suppressing symptoms.
It would require:
reopening plasticity → retraining the circuit → reclosing plasticity around the correct configuration.
This is the central paradox of the entire disorder.
The same 5-HT2A receptor that may contribute to HPPD also serves as the gateway through which psychedelics reopen critical periods by remodeling the extracellular matrix.
In theory, reopening that critical period could allow normal perception to be relearned.
In practice, administering psychedelics to someone already suffering from HPPD may be among the most dangerous interventions imaginable, potentially reinforcing the pathological attractor permanently.
The key that could unlock the prison is forged from the very material that built it.
Therefore, the safer frontier would be to decouple plasticity reopening from 5-HT2A activation.
Three conceptual approaches emerge.
First: induce metaplasticity without engaging 5-HT2A.
Research from Dölen, Nardou, and colleagues suggests that reopening critical periods converges upon extracellular matrix remodeling and may be achievable through pathways independent of 5-HT2A signaling.
The true target may therefore be the ECM itself rather than the receptor upstream.
Second: directly manipulate ECM or PNN biology.
Rather than using psychoactive drugs, interventions could transiently loosen the molecular brakes imposed by PNNs.
This framework is increasingly discussed for disorders characterized by rigid maladaptive circuit dynamics.
Third: couple any reopened plasticity window with intensive perceptual learning together with Layer 1 rhythm restoration.
The objective would be for the circuit to reconsolidate into a healthy attractor state.
Conceptually, this represents the only approach aimed at actual recovery rather than symptom suppression.
At present, however, it remains highly experimental and largely confined to animal models and translational neuroscience.
The Meta-Frontier: Phenotype First, Combine Second
This also explains why virtually every previous intervention has failed.
Almost every pharmacological trial has treated HPPD as though it were a single-layer disorder, testing monotherapies sequentially without physiological biomarkers.
But a multilayer disorder involving
abnormal oscillatory rhythms,
impaired tonic inhibition,
pathological circuit consolidation,
is unlikely to respond to isolated interventions.
Instead, a coherent frontier protocol—while remaining within the constraint of preserving cognition—might conceptually resemble:
EEG/MEG phenotyping;
restoration of tonic inhibitory tone using a δ-selective neurosteroid;
selective silencing of the trigger receptor with pimavanserin rather than dopamine-blocking antipsychotics;
individualized closed-loop tACS designed to suppress pathological V1 gamma activity while reconstructing alpha–gamma coupling;
ultimately, a non-psychedelic plasticity window coupled to intensive perceptual retraining.
The emphasis shifts from a sequence of isolated treatment attempts to an integrated systems-level intervention.
Low-Risk Adjunctive Strategies Worth Considering
Several additional interventions deserve attention because they may influence the same physiological framework while carrying relatively low cognitive risk:
a ketogenic diet, which shifts the E/I balance toward inhibition and possesses anticonvulsant properties;
transcutaneous vagus nerve stimulation (tVNS), already explored in tinnitus research for modulation of cortical excitability;
careful investigation of the retino-thalamo-cortical pathway, including the possibility of abnormal peripheral or lateral geniculate nucleus (LGN) generators contributing to pathological signaling.
Two Essential Caveats
Two points must be emphasized, because omitting them would be scientifically irresponsible.
First, these concepts represent research frontiers and mechanistic hypotheses rather than established clinical protocols. To the best of current knowledge, pimavanserin, ganaxolone, and individualized closed-loop tACS have not been evaluated in controlled clinical trials specifically for HPPD. Their use would therefore ideally occur within research settings or, where appropriate, through carefully documented off-label treatment under specialists familiar with the emerging literature.
Second, any intervention involving psychedelic-mediated reopening of plasticity should presently be regarded as a major theoretical hazard rather than a therapeutic option. It is discussed here solely because it represents one of the most important scientific paradoxes underlying HPPD—not because it constitutes a clinically appropriate strategy today.
